About: Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors
Creator	Domínguez, Angela Godoy, Pere Alonso, Jordi Astray, Jenaro Baricot, Maretva Castro, Ady Delgado-Rodríguez, Miguel Martín, Vicente Tamames, Sonia Cantó, Rafael Gó Nzá Lez-Candelas, Fernando Jesú S Castilla, María Quintana, José Mayoral, José Soldevila, Nuria Sá Ez 15, Marc Tomá S Pumarola,
Source	PMC
abstract	BACKGROUND: The H1N1 influenza pandemic strain has been associated with a poor prognosis in hospitalized patients. The present report evaluates the factors influencing prognosis. METHODS: A total of 813 patients hospitalized with H1N1 influenza in 36 hospitals (nationwide) in Spain were analysed. Detailed histories of variables preceding hospital admission were obtained by interview, validating data on medications and vaccine with their attending physicians. Data on treatment and complications during hospital stay were recorded. As definition of poor outcome, the endpoints of death and admission to intensive care were combined; and as a further outcome, length of stay was used. RESULTS: The mean age was 38.5 years (SD 22.8 years). There were 10 deaths and 79 admissions to intensive care (combined, 88). The use of neuraminidase inhibitors was reported by 495 patients (60.9%). The variables significantly associated with a poor outcome were diabetes (OR = 2.21, 95% CI = 1.21–4.02), corticosteroid therapy (OR = 3.37, 95% CI = 1.39–8.20) and use of histamine-2 receptor antagonists (OR = 2.68, 95% CI = 1.14–6.36), while the use of neuraminidase inhibitors (OR = 0.57, 95% CI = 0.34–0.94) was protective. Neuraminidase inhibitors within the first 2 days after the influenza onset reduced hospital stay by a mean of 1.9 days (95% CI = 4.7–6.6). CONCLUSIONS: The use of neuraminidase inhibitors decreases the length of hospital stay and admission to intensive care and/or death.
has issue date	2012-03-30(xsd:dateTime)
bibo:doi	10.1093/jac/dks098
bibo:pmid	22467633
has license	no-cc
sha1sum (hex)	d8f9951582b4def4c756da8a4fbf388bdb5c7218
schema:url	https://doi.org/10.1093/jac/dks098
resource representing a document's title	Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors
has PubMed Central identifier	PMC3370819
has PubMed identifier	22467633
schema:publication	J Antimicrob Chemother
resource representing a document's body	covid:d8f9951582b4def4c756da8a4fbf388bdb5c7218#body_text
is schema:about of	named entity 'prognosis' named entity 'prognosis' named entity 'Pandemic Influenza' named entity 'Working Group' named entity 'patients' named entity 'influenza' named entity 'REPORT' named entity 'STRAIN' named entity 'BACKGROUND' named entity 'INFLUENZA PANDEMIC' covid:arg/d8f9951582b4def4c756da8a4fbf388bdb5c7218 named entity 'H1N1' named entity 'Prognosis' named entity 'H1N1 influenza pandemic' named entity 'prognosis' named entity 'neuraminidase inhibitors' named entity 'ICU' named entity 'obesity' named entity 'comorbidities' named entity 'COPD' named entity 'saturated model' named entity 'neuraminidase inhibitors' named entity 'Declaration of Helsinki' named entity 'ICU' named entity 'pregnant women' named entity 'neurological impairment' named entity 'logistic regression' named entity 'nasopharyngeal swabs' named entity 'Spain' named entity 'corticosteroid therapy' named entity 'New Zealand Maoris' named entity 'prognosis' named entity 'H1N1 influenza' named entity 'Pneumonia' named entity 'Navarre' named entity 'intensive care' named entity 'ICU' named entity '4.7' named entity 'Catalonia' named entity 'neuraminidase inhibitors' named entity 'disabling neurological disease' named entity 'Jain' named entity 'HIV infection' named entity 'cardiovascular disease' named entity 'normal curve' named entity 'risk factors' named entity 'mechanical ventilation' named entity 'comorbidities' named entity 'mortality rate' named entity 'proton pump inhibitors' named entity 'selection bias' named entity 'antiviral treatment' named entity 'risk factors' named entity 'analysis of covariance' named entity 'probability' named entity 'multivariate analysis' named entity 'cardiovascular disease' named entity 'H1N1' named entity 'receptor antagonists' named entity 'vaccine' named entity 'Argentina' named entity 'adverse outcome' named entity 'ICU' named entity 'antibiotics' named entity 'Andalusia'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software